A randomised, double blind, placebo controlled, multicentre phase III trial to evaluate the efficacy and safety of adding bevacizumab to gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
- Conditions
- Metastatic pancreatic cancer adenocarcinoma.MedDRA version: 6.1Level: PTClassification code 10033610
- Registration Number
- EUCTR2004-002854-78-IT
- Lead Sponsor
- ROCHE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method